and the DCTH overall survival median will keep moving up as those who have complete reponse live cancer free and a long time which can only be a projection now. Certainly going to see overall survival over 2 years with DCTH.
DCTH beats Stivarga hands down, so Bayer will want DCTH
More i think about it the more valuation increases. The tech parlays into crc downstream. Widespread adoption. A tech play and pharma play at the same time.